Literature DB >> 6222909

Role of human factor I and C3b receptor in the cleavage of surface-bound C3bi molecules.

R G Medicus, J Melamed, M A Arnaout.   

Abstract

Control of functions mediated by the third component of complement (C3) depends on the rate of generation and degradation of biologically active C3 fragments. To evaluate the mechanisms of degradation of active C3 fragments, the role of the control protein C3b/C4b inactivator (factor I) was investigated under conditions approximating those found in vivo, i.e. in the presence of plasma. The breakdown of human erythrocyte-bound C3bi molecules in serum or plasma was mediated only by factor I, since factor I-deficient or -depleted plasma was inactive until reconstituted with highly purified factor I. The rate of cleavage of C3bi bound to human erythrocytes by purified factor I was not affected by the presence or absence of beta 1H (factor H). The released breakdown product of C3bi has been shown to be C3c antigenically and on polyacrylamide gel electrophoresis in the presence of sodium dodecyl sulfate. Two different monospecific antibodies to the human C3b receptor totally abrogated factor I-mediated cleavage of cell-bound C3bi, suggesting that the C3b receptor (but not factor H) is required as an obligate cofactor. The rate of this C3b receptor-dependent, factor I-mediated cleavage of bound C3bi is strongly regulated by the surface to which C3bi is bound. Whereas C3bi bound to particulate nonactivators of the alternative complement pathway such as human erythrocytes is rapidly degraded by this mechanism, the rate of cleavage of C3bi bound to activators is significantly slower. These data suggest a physiologic role of C3b receptors in the degradation of biologically active C3 fragments deposited on host tissues. They also suggest that C3bi molecules on restricted surfaces are relatively stable and can thereby interact with complement C3 receptors in vivo.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6222909     DOI: 10.1002/eji.1830130607

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  19 in total

1.  CR2-mediated activation of the complement alternative pathway results in formation of membrane attack complexes on human B lymphocytes.

Authors:  C H Nielsen; H V Marquart; W M Prodinger; R G Leslie
Journal:  Immunology       Date:  2001-12       Impact factor: 7.397

2.  Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection.

Authors:  H E Feucht; E Felber; M J Gokel; G Hillebrand; U Nattermann; C Brockmeyer; E Held; G Riethmüller; W Land; E Albert
Journal:  Clin Exp Immunol       Date:  1991-12       Impact factor: 4.330

3.  Immune complexes and erythrocyte CR1 (complement receptor type 1): effect of CR1 numbers on binding and release reactions.

Authors:  Y C Ng; J A Schifferli; M J Walport
Journal:  Clin Exp Immunol       Date:  1988-03       Impact factor: 4.330

Review 4.  The properdin pathway: an "alternative activation pathway" or a "critical amplification loop" for C3 and C5 activation?

Authors:  Richard A Harrison
Journal:  Semin Immunopathol       Date:  2017-11-22       Impact factor: 9.623

Review 5.  CR1 and the cell membrane proteins that bind C3 and C4. A basic and clinical review.

Authors:  J G Wilson; N A Andriopoulos; D T Fearon
Journal:  Immunol Res       Date:  1987       Impact factor: 2.829

Review 6.  The alternative pathway of complement.

Authors:  M K Pangburn; H J Müller-Eberhard
Journal:  Springer Semin Immunopathol       Date:  1984

Review 7.  The complement system: 1983.

Authors:  J E Volanakis
Journal:  Surv Immunol Res       Date:  1984

Review 8.  The role of complement in the induction and regulation of immune responses.

Authors:  T G Egwang; A D Befus
Journal:  Immunology       Date:  1984-02       Impact factor: 7.397

9.  Correlation of the activation of the fourth component of complement (C4) with disease activity in systemic lupus erythematosus.

Authors:  G Senaldi; V A Makinde; D Vergani; D A Isenberg
Journal:  Ann Rheum Dis       Date:  1988-11       Impact factor: 19.103

10.  Activated C3 (C3b) in the nephritic glomerulus.

Authors:  C Pan; C F Strife; A J McAdams; C D West
Journal:  Pediatr Nephrol       Date:  1993-08       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.